CD22 and cancer: Bi-specific CARs that have shown to be effective anti-cancer agents include those targeting CD70-B7-H3 for several solid tumors [37], those targeting CD5–CD7 for leukemia [38], CD19–CD20 or CD19–CD22 for B-cell malignancies [39, 40].